Comparison tool

Livagen vs Epithalon side-by-side

Stack up to four peptides by evidence status, mechanisms, study dosing, side effects, and references.

Selected (2/4)

LivagenEpithalon

Share this peptide comparison

Property	Livagen	Epithalon
Category	Bioregulators	Bioregulators
Also known as	Lys-Glu-Asp-Ala, KEDA	Epitalon, Epithalone, AGAG
FDA approved	No	No
Clinical status	Preclinical research; reported as approved in Russia as a supplement Pre Preclinical I Phase I II Phase II III Phase III IV Phase IV FDA FDA approved	Investigational; primarily Russian research. Source notes current FDA Category 2 status pending formal reclassification activity in 2026. Pre Preclinical I Phase I II Phase II III Phase III IV Phase IV FDA FDA approved
What to expect	Gene expression, cellular aging, liver health	Longevity, telomere support, anti-aging, sleep
How it works	Livagen is presented as a short peptide bioregulator with a proposed epigenetic mode of action. The supplied source describes in vitro findings in which KEDA was associated with less condensed pericentromeric heterochromatin and increased ribosomal gene activity in cells from older donors. This remains a hypothesis based on cell-level work; the source does not establish how a tetrapeptide would produce selective nuclear effects in humans.	Epithalon is proposed to act through telomerase-related biology, with cell-culture reports describing telomerase activity and telomere elongation in human fibroblasts. The source also notes possible effects on melatonin, antioxidant defenses, and gene expression in pineal-hypothalamic pathways. Translation from these observations to meaningful human anti-aging outcomes remains unproven in the supplied evidence.
Typical dosing	10-20 mg daily · Once or twice daily · 10-30 day cycles · Oral capsules or sublingual	5-10 mg daily for 10-20 days · Once daily in cycles · 10-20 days
Research dosing	10-20 mg daily · 10-30 day cycles · Oral capsules or sublingual	5-10 mg daily for 10-20 days · 10-20 day cycles · Subcutaneous or intramuscular injection
Typical duration	10-30 day cycles	10-20 day cycles
Administration	Oral capsules or sublingual	Subcutaneous or intramuscular injection
Timing	Morning on an empty stomach Take on an empty stomach	Before bed With or without food
Evidence level	Preclinical	Clinical Trials
Possible side effects	Generally reported as well tolerated (Source-reported safety characterization; detailed adverse event data are not provided.) Limited safety data outside Russia (Safety evidence is described as geographically and evidentially limited.) Not FDA approved (This is regulatory status, not an adverse effect.)	Generally well-tolerated (Reported in the source, but tolerability evidence is limited by the available research base.) Injection site reactions (Reported as a possible effect with injectable administration.) Mild headache (Source describes this as transient.) +3 more Sleep disturbances (Reported as a possible effect; frequency is not established.) Risk of immunogenicity (Listed as a potential risk rather than a quantified event rate.) Long-term safety not established (The source explicitly notes uncertainty about long-term safety.)
Research summary	The supplied research description centers on a narrow body of mechanistic work attributed mainly to Khavinson, Lezhava, and collaborators. It highlights a 2002 Bulletin of Experimental Biology and Medicine report in which cultured lymphocytes from older donors were exposed to Livagen and assessed for ribosomal gene activity and heterochromatin structure. Related peptide bioregulators were reported in the same research line. The evidence described is cell-level and mechanistic rather than clinical, and the source states that randomized human trials for Livagen were not identified.	The supplied research narrative gives greatest weight to laboratory and animal data. It cites a 2003 report by Khavinson and colleagues on telomerase activity and telomere changes in cultured human fibroblasts, plus a 2025 review discussing geroprotective and neuroendocrine research. Animal studies are described as reporting lifespan and tumor-incidence findings. Human evidence is characterized as limited, often small or open-label, and not independently replicated at the scale needed to prove lifespan extension or reliable telomere-length effects in people.
References	Source Source +2 more Source Source	PubMed PubMed +2 more WikipediaEpitalon Springer
Full profile	View Details	View Details

Save this comparison

Keep this research set handy with a free PeptiGuide account.

Save this comparison - free account

Track your peptide journey

Turn research into a private protocol log when you are ready.

Track your peptide journey

Educational use only. This information is aggregated from public research and community reports. It is not medical advice, and dosing details are descriptive, not recommendations. Always consult a qualified healthcare professional.

Property

Livagen

Epithalon

Category

Bioregulators

Also known as

Lys-Glu-Asp-Ala, KEDA

Epitalon, Epithalone, AGAG

FDA approved

Clinical status

Preclinical research; reported as approved in Russia as a supplement

Pre
Preclinical
I
Phase I
II
Phase II
III
Phase III
IV
Phase IV
FDA
FDA approved

Investigational; primarily Russian research. Source notes current FDA Category 2 status pending formal reclassification activity in 2026.

Pre
Preclinical
I
Phase I
II
Phase II
III
Phase III
IV
Phase IV
FDA
FDA approved

What to expect

Gene expression, cellular aging, liver health

Longevity, telomere support, anti-aging, sleep

How it works

Livagen is presented as a short peptide bioregulator with a proposed epigenetic mode of action. The supplied source describes in vitro findings in which KEDA was associated with less condensed pericentromeric heterochromatin and increased ribosomal gene activity in cells from older donors. This remains a hypothesis based on cell-level work; the source does not establish how a tetrapeptide would produce selective nuclear effects in humans.

Epithalon is proposed to act through telomerase-related biology, with cell-culture reports describing telomerase activity and telomere elongation in human fibroblasts. The source also notes possible effects on melatonin, antioxidant defenses, and gene expression in pineal-hypothalamic pathways. Translation from these observations to meaningful human anti-aging outcomes remains unproven in the supplied evidence.

Typical dosing

10-20 mg daily · Once or twice daily · 10-30 day cycles · Oral capsules or sublingual

5-10 mg daily for 10-20 days · Once daily in cycles · 10-20 days

Research dosing

10-20 mg daily · 10-30 day cycles · Oral capsules or sublingual

5-10 mg daily for 10-20 days · 10-20 day cycles · Subcutaneous or intramuscular injection

Typical duration

10-30 day cycles

10-20 day cycles

Administration

Oral capsules or sublingual

Subcutaneous or intramuscular injection

Timing

Morning on an empty stomach

Take on an empty stomach

Before bed

With or without food

Evidence level

Preclinical

Clinical Trials

Possible side effects

Generally reported as well tolerated (Source-reported safety characterization; detailed adverse event data are not provided.)
Limited safety data outside Russia (Safety evidence is described as geographically and evidentially limited.)
Not FDA approved (This is regulatory status, not an adverse effect.)

Generally well-tolerated (Reported in the source, but tolerability evidence is limited by the available research base.)
Injection site reactions (Reported as a possible effect with injectable administration.)
Mild headache (Source describes this as transient.)

+3 more

Sleep disturbances (Reported as a possible effect; frequency is not established.)
Risk of immunogenicity (Listed as a potential risk rather than a quantified event rate.)
Long-term safety not established (The source explicitly notes uncertainty about long-term safety.)

Research summary

The supplied research description centers on a narrow body of mechanistic work attributed mainly to Khavinson, Lezhava, and collaborators. It highlights a 2002 Bulletin of Experimental Biology and Medicine report in which cultured lymphocytes from older donors were exposed to Livagen and assessed for ribosomal gene activity and heterochromatin structure. Related peptide bioregulators were reported in the same research line. The evidence described is cell-level and mechanistic rather than clinical, and the source states that randomized human trials for Livagen were not identified.

The supplied research narrative gives greatest weight to laboratory and animal data. It cites a 2003 report by Khavinson and colleagues on telomerase activity and telomere changes in cultured human fibroblasts, plus a 2025 review discussing geroprotective and neuroendocrine research. Animal studies are described as reporting lifespan and tumor-incidence findings. Human evidence is characterized as limited, often small or open-label, and not independently replicated at the scale needed to prove lifespan extension or reliable telomere-length effects in people.

References

Source Source

+2 more

Source Source

PubMed PubMed

+2 more

WikipediaEpitalon Springer

Full profile

View Details